The direct causes of Alzheimer's disease continues to elude the scientific community, which makes creating treatments for it exceedingly difficult. We have seen a number of high-profile failures lately, and now Baxter International can be added to that list. Shares were down slightly, as drug Gammagard failed to preserve or reduce the decline of cognitive function in patients during phase 3 trials.
In this video, health-care analyst David Williamson discusses what's next for Baxter and other promising drugs to treat Alzheimer's that investors need to have on their radars.
Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.
Follow David on Twitter: @MotleyDavid.